Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437659 | 1.00 | CA12 (0.36) | CA12CA14CA2CA1CA7 | |
| SCHEMBL17437662 | 1.00 | CA12 (0.36) | CA12CA14CA2CA1CA7 | |
| SCHEMBL17489593 | 0.89 | CA12 (0.40) | CA12CA14CA2CA1CA7 | |
| SCHEMBL10015600 | 0.89 | BTK (0.39) | BTKGAAL3MBTL1 | |
| SCHEMBL17449867 | 0.86 | CA12 (0.40) | CA12CA14CA2CA1CA7 | |
| SCHEMBL17437671 | 0.83 | CYP3A4 (0.37) | CA12CA14CA2CA1CA7 | |
| SCHEMBL17437672 | 0.83 | CYP3A4 (0.37) | CA12CA14CA2CA1CA7 | |
| SCHEMBL17437673 | 0.83 | CYP3A4 (0.37) | CA12CA14CA2CA1CA7 | |
| SCHEMBL16664800 | 0.80 | BTK (0.37) | BTK | |
| SCHEMBL10063105 | 0.79 | MAOB (0.42) | CA12CA14CA1CA7BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019004114-A1 | PRODUCTION METHOD FOR DIAMINE DERIVATIVE BY FLOW SYNTHESIS | 第一三共株式会社 | 2019-01-03 | — | — | WO | disclosed |
| EP-2980067-B1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9447118-B2 | Preparation method of optically active diamine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-20 | — | — | US | disclosed |
| EP-2980067-A1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20160016974-A1 | PREPARATION METHOD OF OPTICALLY ACTIVE DIAMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016974-A1 | PREPARATION METHOD OF OPTICALLY ACTIVE DIAMINE COMPOUND | F12, F8, F11 | CA12 2520/4885CA14 1145/4885CA2 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.